Long-term response in patients receiving HAART including nelfinavir: Experience from two Italian centers

A. Castagna, A. Danise, B. Giudici, Adriano Lazzarin, F. Castelli, G. Paraninfo, G. Carosi, P. L. Carriero

Research output: Contribution to journalArticlepeer-review


Many studies have demonstrated that the long-term, virological, immunological and clinical effectiveness of highly active antiretroviral therapy (HAART) is mainly related to durable suppression of viral replication. Among the specific antiretroviral agents available today, nelfinavir has been widely used in the last 3 years. This open label, non comparative, retrospective study on 307 patients living with HIV aimed to evaluate the effectiveness of an antiretroviral (ART) regimen including nelfinavir as first-line HAART in terms of rate and durability of viro-immunological response. Most patients, 258/307 (84%), were pre-treated whereas only 49/307 (16%) were treatment naïve. The median baseline CD4 cell count was 223 cells/mm3 for naïve patients and 317 cells/mm3 for experienced patients whereas median HIV RNA values were 2,500 and 82,000 copies/ml for experienced and naïve patients respectively. Median times spent on nelfinavir were 839 and 897 days for experienced and naïve patients respectively, with 171/258 pre-treated patients (66%) remaining on nelfinavir-based therapy up to 24 months. Overall, the mean CD4 increase was 196 cells/mm3 with a relevant increment of 165 in experienced patients and 367 cells/mm3 in naïve patients (p10 and in experienced patients -0.53 log10 (p

Original languageEnglish
Pages (from-to)189-193
Number of pages5
JournalJournal of Chemotherapy
Issue number2
Publication statusPublished - 2002


  • Antiretroviral therapy
  • HIV
  • Nelfinavir

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Microbiology (medical)


Dive into the research topics of 'Long-term response in patients receiving HAART including nelfinavir: Experience from two Italian centers'. Together they form a unique fingerprint.

Cite this